We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+8.17%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$54.9M
AUM Growth
-$124M
Cap. Flow
-$104M
Cap. Flow %
-189.39%
Top 10 Hldgs %
82.94%
Holding
32
New
1
Increased
5
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$1.34M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$239K
3
GERN icon
Geron
GERN
+$117K
4
NBIX icon
Neurocrine Biosciences
NBIX
+$117K
5
MIST icon
Milestone Pharmaceuticals
MIST
+$64.3K

Top Sells

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$1.34M
2
HUMA icon
Humacyte
HUMA
+$731K
3
TVTX icon
Travere Therapeutics
TVTX
+$601K
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$487K
5
REPL icon
Replimune Group
REPL
+$347K

Sector Composition

Rank Sector Weight
1 Healthcare 50.93%
2 Financials 1.56%
3 Consumer Discretionary 1.02%
4 Technology 0.08%
5 Energy 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$16.7M 30.51%
82,500
-165,000
-67% -$33.3M
ARDX icon
2
Ardelyx
ARDX
$1.25B
$6.35M 11.57%
856,667
-190,000
-18% -$1.34M
INSM icon
3
Insmed
INSM
$23.2B
$4.71M 8.59%
70,335
– –
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$4.64M 8.45%
50,000
– –
MIST icon
5
Milestone Pharmaceuticals
MIST
$144M
$3.09M 5.63%
2,340,207
+40,000
+2% +$64.3K
GERN icon
6
Geron
GERN
$924M
$2.67M 4.87%
630,000
+30,000
+5% +$117K
MRNS
7
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.47M 4.51%
2,114,827
-4,309
-0.2% -$10.8K
KNSA icon
8
Kiniksa Pharmaceuticals
KNSA
$4.84B
$1.95M 3.56%
104,691
-26,000
-20% -$487K
MIRM icon
9
PUT
Mirum Pharmaceuticals
MIRM
$6.9B
$1.54M 2.8%
45,000
– –
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.84B
$1.33M 2.43%
65,000
– –
BBIO icon
11
BridgeBio Pharma
BBIO
$16.5B
$1.24M 2.26%
+49,000
New +$1.34M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$1.16M 2.11%
82,500
– –
NBIX icon
13
Neurocrine Biosciences
NBIX
$17.7B
$1.15M 2.1%
8,350
+850
+11% +$117K
FENC icon
14
Fennec Pharmaceuticals
FENC
$347M
$1.04M 1.89%
170,000
– –
MLYS icon
15
Mineralys Therapeutics
MLYS
$2.35B
$924K 1.69%
79,000
+19,000
+32% +$239K
NFYS
16
DELISTED
Enphys Acquisition Corp.
NFYS
$858K 1.56%
78,125
– –
JSPR icon
17
Jasper Therapeutics
JSPR
$22.9M
$726K 1.32%
32,000
– –
BLUE
18
DELISTED
bluebird bio
BLUE
$668K 1.22%
33,913
-8,500
-20% -$170K
BFI
19
DELISTED
BurgerFi International, Inc. Common Stock
BFI
$557K 1.02%
2,745,938
– –
RGNX icon
20
Regenxbio
RGNX
$623M
$424K 0.77%
36,250
+3,750
+12% +$58.4K
MCRB icon
21
Seres Therapeutics
MCRB
$47.9M
$247K 0.45%
17,038
– –
LUMO
22
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$211K 0.38%
90,794
– –
MSFT icon
23
Microsoft
MSFT
$2.84T
$44.7K 0.08%
100
– –
SPRB
24
Spruce Biosciences
SPRB
$119M
$38.8K 0.07%
1,000
– –
BFIIW
25
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
$26.3K 0.05%
2,083,438
– –
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Lion Point Capital held 32 positions worth $54.9M, down 69% from $179M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Lion Point Capital withdrew a net $104M in Q2 2024, closing 5 positions and reducing 6 holdings. Its most notable exit was Humacyte, an estimated $731K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 17% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Lion Point Capital opened a new position in BridgeBio Pharma worth $1.24M.

  • Lion Point Capital's largest Q2 2024 buy was BridgeBio Pharma: 49,000 shares worth $1.24M.
  • Lion Point Capital added most to Mineralys Therapeutics in Q2 2024, an estimated $239K increase.
  • Lion Point Capital's biggest Q2 2024 reduction was Ardelyx, cutting an estimated $1.34M.
  • Lion Point Capital fully exited Humacyte in Q2 2024, selling an estimated $731K.
  • Lion Point Capital's ten largest holdings make up 83% of its $54.9M portfolio in Q2 2024.
  • Lion Point Capital opened 1 new position and closed 5 in Q2 2024.
  • Lion Point Capital's portfolio value fell 69% quarter-over-quarter to $54.9M.

Based on Lion Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.